MCID: PRP026
MIFTS: 34

Peripheral Retinal Degeneration malady

Categories: Eye diseases

Aliases & Classifications for Peripheral Retinal Degeneration

Aliases & Descriptions for Peripheral Retinal Degeneration:

Name: Peripheral Retinal Degeneration 12 14
Peripheral Degeneration of Retina 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:12161
ICD10 33 H35.4 H35.40
ICD9CM 35 362.6 362.60
NCIt 47 C34919
UMLS 69 C1320640

Summaries for Peripheral Retinal Degeneration

MalaCards based summary : Peripheral Retinal Degeneration, also known as peripheral degeneration of retina, is related to parachute tricuspid valve and wilms tumor 2. An important gene associated with Peripheral Retinal Degeneration is PRPH2 (Peripherin 2), and among its related pathways/superpathways are Endochondral Ossification and Cell adhesion_ECM remodeling. The drugs Bevacizumab and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include retina and eye, and related phenotypes are pigmentation and vision/eye

Related Diseases for Peripheral Retinal Degeneration

Diseases related to Peripheral Retinal Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
id Related Disease Score Top Affiliating Genes
1 parachute tricuspid valve 10.2 PRPH2 ROM1
2 wilms tumor 2 10.2 CLN3 CLN5
3 restless legs syndrome 6 10.2 BEST1 PRPH2
4 bleeding disorder, platelet-type, 16, autosomal dominant 10.2 CLN3 CLN5
5 bone fracture 10.2 BEST1 PRPH2
6 medulloblastoma 10.2 CLN3 CLN5
7 transaldolase deficiency 10.2 CLN3 CLN5
8 brugada syndrome 6 10.2 BEST1 RPGR
9 chd2-related neurodevelopmental disorders 10.2 BEST1 ROM1
10 brody myopathy 10.1 CLN3 CLN5
11 retinitis 10.1
12 retinal degeneration 10.1
13 hypertrichotic osteochondrodysplasia 10.1 PRPH2 ROM1 RPGR
14 alcohol-related neurodevelopmental disorder 10.1 BEST1 PRPH2 ROM1
15 neonatal abstinence syndrome 10.1 COL2A1 PRPH2
16 nephropathy familial with hyperuricemia 10.1 MBL2 ROM1
17 choriodal dystrophy, central areolar 2 10.1 PRPH2 ROM1 TF
18 epileptic encephalopathy, early infantile, 1 10.0 BEST1 COL2A1
19 adult liposarcoma 9.9 BEST1 PRPH2 ROM1 RPGR
20 polyhydramnios 9.9 BEST1 PRPH2 ROM1 RPGR
21 liver cirrhosis 9.9 BEST1 PRPH2 ROM1 RPGR
22 partial central choroid dystrophy 9.9 PRPH2 TIMP3
23 puerperal pulmonary embolism 9.9 ROM1 RPGR TIMP3
24 monofixation syndrome 9.8 PRPH2 TIMP3
25 myopia 9.8
26 vitreoretinochoroidopathy 9.8 BEST1 PRPH2 ROM1 TIMP3
27 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 9.8 BEST1 PRPH2 TIMP3
28 primary congenital glaucoma 9.6
29 sertoli cell-only syndrome 9.3 BEST1 CLN3 DHDDS PRPH2 ROM1 RPGR
30 blessig's cysts 8.6 BEST1 CLN3 CLN5 COL2A1 DHDDS MBL2

Graphical network of the top 20 diseases related to Peripheral Retinal Degeneration:



Diseases related to Peripheral Retinal Degeneration

Symptoms & Phenotypes for Peripheral Retinal Degeneration

MGI Mouse Phenotypes related to Peripheral Retinal Degeneration:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.26 BEST1 PRPH2 RPGR TIMP3
2 vision/eye MP:0005391 9.23 RPGR TIMP3 BEST1 CLN3 CLN5 COL2A1

Drugs & Therapeutics for Peripheral Retinal Degeneration

Drugs for Peripheral Retinal Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
3
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 299-42-3 9294
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7
Norgestimate Approved Phase 4 35189-28-7 6540478
8
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-82-4 7028
9
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
10
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
11
Diclofenac Approved, Vet_approved Phase 4,Phase 1 15307-86-5 3033
12
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
13
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
14
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
15
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
16
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
17
Temazepam Approved Phase 4 846-50-4 5391
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
20
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
21
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
22
Difluprednate Approved Phase 4 23674-86-4 443936
23
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
24
alemtuzumab Approved, Investigational Phase 4 216503-57-0
25
Methotrexate Approved Phase 4,Phase 3 1959-05-2, 59-05-2 126941
26
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
27
Choline Approved, Nutraceutical Phase 4 62-49-7 305
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 54575, 6560146 143
30
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2,Phase 1 91714-94-2 60726
31 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
32 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
33 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
34 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
36 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
37 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
38 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3,Phase 1
39 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
40 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
41 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
42 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
43 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
47
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 2
49 Antibiotics, Antitubercular Phase 4,Phase 2
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 193)
id Name Status NCT ID Phase
1 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
2 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
3 Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections Unknown status NCT00690313 Phase 4
4 Pain Perception at Laser Treatment Completed NCT01033968 Phase 4
5 Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease Completed NCT02233023 Phase 4
6 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4
7 Combined Therapy in Age-Related Macular Degeneration (ARMD) Completed NCT00805649 Phase 4
8 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
9 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4
10 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4
11 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4
12 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4
13 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4
14 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4
15 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4
16 Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery Completed NCT01542190 Phase 4
17 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4
18 Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification Completed NCT02084576 Phase 4
19 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4
20 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4
21 Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery Completed NCT01395069 Phase 4
22 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4
23 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4
24 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4
25 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
26 Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients Completed NCT02646072 Phase 4
27 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4
28 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4
29 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03046693 Phase 4
30 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4
31 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Recruiting NCT02684084 Phase 4
32 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Recruiting NCT02374060 Phase 4
33 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Recruiting NCT02419378 Phase 4
34 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4
35 Topical Treatment for Uveitic Macular Edema Not yet recruiting NCT01939691 Phase 4
36 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4
37 Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema Unknown status NCT01523314 Phase 2, Phase 3
38 Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema Unknown status NCT00780780 Phase 3
39 Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A Completed NCT00346333 Phase 3
40 Retaane® in Age-Related Macular Degeneration Completed NCT00569569 Phase 2, Phase 3
41 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3
42 Branch Vein Occlusion Study Completed NCT00000162 Phase 3
43 Laser and Medical Treatment of Diabetic Macular Edema Completed NCT00050479 Phase 3
44 An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects Completed NCT00709449 Phase 2, Phase 3
45 Age-Related Eye Disease Study 2 (AREDS2) Completed NCT00345176 Phase 3
46 The Effect of Intravitreal Ozurdex on DME After Cataract Surgery Completed NCT01748487 Phase 3
47 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Completed NCT00168337 Phase 3
48 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema Completed NCT00168389 Phase 3
49 Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone Completed NCT01892163 Phase 3
50 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Completed NCT01449682 Phase 3

Search NIH Clinical Center for Peripheral Retinal Degeneration

Genetic Tests for Peripheral Retinal Degeneration

Anatomical Context for Peripheral Retinal Degeneration

MalaCards organs/tissues related to Peripheral Retinal Degeneration:

39
Retina, Eye

Publications for Peripheral Retinal Degeneration

Articles related to Peripheral Retinal Degeneration:

id Title Authors Year
1
PERIPHERAL RETINAL DEGENERATIONS AND RHEGMATOGENOUS DETACHMENT IN PRIMARY CONGENITAL GLAUCOMA. ( 26200515 )
2015
2
Prevalence and characteristics of peripheral retinal degeneration in Chinese adults with high myopia: a cross-sectional prevalence survey. ( 15829850 )
2005
3
A peripherin/retinal degeneration slow mutation (Pro-210-Arg) associated with macular and peripheral retinal degeneration. ( 7862413 )
1995
4
Dominant macular subretinal neovascularization with peripheral retinal degeneration. ( 2446233 )
1987
5
Animal model: peripheral retinal degeneration in rats. ( 525679 )
1979
6
The classification and terminology of peripheral retinal degeneration. ( 1160882 )
1975
7
Peripheral retinal degeneration in high myopia. ( 5546858 )
1971
8
Peripheral retinal degeneration. ( 6054908 )
1967
9
Relationship between ophthalmoscopic and histopathologic findings in peripheral retinal degeneration. ( 5604436 )
1967
10
Familial association of central and peripheral retinal degeneration. ( 13890923 )
1961

Variations for Peripheral Retinal Degeneration

Expression for Peripheral Retinal Degeneration

Search GEO for disease gene expression data for Peripheral Retinal Degeneration.

Pathways for Peripheral Retinal Degeneration

Pathways related to Peripheral Retinal Degeneration according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.77 COL2A1 TIMP3
2 10.41 COL2A1 TIMP3

GO Terms for Peripheral Retinal Degeneration

Cellular components related to Peripheral Retinal Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 8.62 PRPH2 RPGR

Biological processes related to Peripheral Retinal Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein catabolic process GO:0030163 9.16 CLN3 CLN5
2 visual perception GO:0007601 9.1 BEST1 COL2A1 PRPH2 ROM1 RPGR TIMP3
3 lysosomal lumen acidification GO:0007042 8.96 CLN3 CLN5

Molecular functions related to Peripheral Retinal Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme inhibitor activity GO:0004857 8.96 TF TIMP3
2 mannose binding GO:0005537 8.62 CLN5 MBL2

Sources for Peripheral Retinal Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....